JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

Search

Eli Lilly and Co.

Fermé

SecteurSoins de santé

757.36 3.2

Résumé

Variation du prix de l'action

24h

Actuel

Min

732.88

Max

758.64

Chiffres clés

By Trading Economics

Revenu

-6.1B

2.8B

Ventes

-804M

13B

P/E

Moyenne du Secteur

61.579

56.602

BPA

3.34

Rendement du dividende

0.82

Marge bénéficiaire

21.678

Employés

47,000

EBITDA

-2B

4.2B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+37.39% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.82%

2.45%

Prochains Résultats

6 août 2025

Date du Prochain Dividende

10 juin 2025

Date du Prochain Détachement de Dividende

16 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-149B

678B

Ouverture précédente

754.16

Clôture précédente

757.36

Sentiment de l'Actualité

By Acuity

63%

37%

335 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Eli Lilly and Co. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 mai 2025, 11:24 UTC

Résultats

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

22 avr. 2025, 09:26 UTC

Principaux Mouvements du Marché

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18 avr. 2025, 15:57 UTC

Principaux Mouvements du Marché

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

12 mai 2025, 22:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 17:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 mai 2025, 17:01 UTC

Actualités

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mai 2025, 13:56 UTC

Résultats

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mai 2025, 11:18 UTC

Résultats

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mai 2025, 09:30 UTC

Actualités

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 mai 2025, 20:30 UTC

Actualités

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 mai 2025, 04:05 UTC

Acquisitions, Fusions, Rachats

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 mai 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 mai 2025, 14:07 UTC

Résultats

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 12:47 UTC

Résultats

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1 mai 2025, 12:00 UTC

Actualités

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1 mai 2025, 11:58 UTC

Résultats

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 11:06 UTC

Résultats

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 10:48 UTC

Résultats

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1 mai 2025, 10:48 UTC

Résultats

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1 mai 2025, 10:45 UTC

Résultats

Eli Lilly 1Q Adj EPS $3.34 >LLY

1 mai 2025, 10:45 UTC

Résultats

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1 mai 2025, 10:45 UTC

Résultats

Eli Lilly 1Q Net $2.76B >LLY

1 mai 2025, 10:45 UTC

Résultats

Eli Lilly 1Q Rev $12.73B >LLY

1 mai 2025, 10:45 UTC

Résultats

Eli Lilly 1Q EPS $3.06 >LLY

1 mai 2025, 10:45 UTC

Résultats

Eli Lilly Sees FY Adj EPS $20.78-Adj EPS $22.28 >LLY

30 avr. 2025, 09:30 UTC

Actualités

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

28 avr. 2025, 13:58 UTC

Actualités

IBM, Apple, Eli Lilly: Tracking Corporate Spending Pledges Under Trump -- WSJ

22 avr. 2025, 09:31 UTC

Actions en Tendance

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17 avr. 2025, 18:27 UTC

Actualités

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

Comparaison

Variation de prix

Eli Lilly and Co. prévision

Objectif de Prix

By TipRanks

37.39% hausse

Prévisions sur 12 Mois

Moyen 983.13 USD  37.39%

Haut 1,124 USD

Bas 700 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

18

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

N/A / 884.54Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

335 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.